PRODUCT INFORMATION

SNX-2112

Item No. 22359

CAS Registry No.:	908112-43-6
Formal Name:	2-[(*trans*-4-hydroxycyclohexyl)amino]-4-[4,5,6,7-tetrahydro-6,6-dimethyl-4-oxo-3-(trifluoromethyl)-1H-indazol-1-yl]-benzamide
Synonym:	PF-04928473
MF:	$C_{23}H_{27}F_3N_4O_3$
FW:	464.5
Purity:	≥98%
UV/Vis.:	λ_{max}: 251, 360 nm
Supplied as:	A crystalline solid
Storage:	-20°C
Stability:	≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

SNX-2112 is supplied as a crystalline solid. A stock solution may be made by dissolving the SNX-2112 in the solvent of choice. SNX-2112 is soluble in organic solvents such as DMSO and dimethyl formamide, which should be purged with an inert gas. The solubility of SNX-2112 in these solvents is approximately 1 and 0.25 mg/ml, respectively.

SNX-2112 is sparingly soluble in aqueous buffers. For maximum solubility in aqueous buffers, SNX-2112 should first be dissolved in DMSO and then diluted with the aqueous buffer of choice. SNX-2112 has a solubility of approximately 0.5 mg/ml in a 1:1 solution of DMSO:PBS (pH 7.2) using this method. We do not recommend storing the aqueous solution for more than one day.

Description

SNX-2112 is a potent inhibitor of heat shock protein 90 (Hsp90) with a K_d value of 30 nM.[1] *In vitro*, SNX-2112 induces down-regulation of the client proteins HER2 and Akt. It inhibits proliferation in a panel of cancer cell lines (IC_{50}s = 10-50 nM). SNX-2112 (150 mg/kg) completely inhibits tumor growth in a BT474 breast cancer mouse xenograft model. SNX-2112 is also the active metabolite of prodrug SNX-5542 and preferentially accumulates in tumor tissue of mice treated with a single oral dose of 75 mg/kg SNX-5542. Formulations containing SNX-2112 are under clinical investigation for treatment of refractory solid tumors.[2]

References

1. Chandarlapaty, S., Sawai, A., Ye, Q., *et al.* SNX2112, a synthetic heat shock protein 90 inhibitor, has potent antitumor activity against HER kinase-dependent cancers. *Clin. Cancer Res.* **14(1)**, 240-248 (2008).
2. Infante, J.R., Weiss, G.J., Jones, S., *et al.* Phase I dose-escalation studies of SNX-5422, an orally bioavailable heat shock protein 90 inhibitor, in patients with refractory solid tumours. *Eur. J. Cancer* **50(17)**, 2897-2904 (2014).

CAYMAN CHEMICAL
1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA
PHONE: [800] 364-9897
[734] 971-3335
FAX: [734] 971-3640
CUSTSERV@CAYMANCHEM.COM
WWW.**CAYMANCHEM**.COM